Buonadonna, A.; Scalone, S.; Lombardi, D.; Fumagalli, A.; Guglielmi, A.; Lestuzzi, C.; Polesel, J.; Canzonieri, V.; Lamon, S.; Giovanis, P.;
et al. Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas. Cancers 2023, 15, 5036.
https://doi.org/10.3390/cancers15205036
AMA Style
Buonadonna A, Scalone S, Lombardi D, Fumagalli A, Guglielmi A, Lestuzzi C, Polesel J, Canzonieri V, Lamon S, Giovanis P,
et al. Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas. Cancers. 2023; 15(20):5036.
https://doi.org/10.3390/cancers15205036
Chicago/Turabian Style
Buonadonna, Angela, Simona Scalone, Davide Lombardi, Arianna Fumagalli, Alessandra Guglielmi, Chiara Lestuzzi, Jerry Polesel, Vincenzo Canzonieri, Stefano Lamon, Petros Giovanis,
and et al. 2023. "Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas" Cancers 15, no. 20: 5036.
https://doi.org/10.3390/cancers15205036
APA Style
Buonadonna, A., Scalone, S., Lombardi, D., Fumagalli, A., Guglielmi, A., Lestuzzi, C., Polesel, J., Canzonieri, V., Lamon, S., Giovanis, P., Gagno, S., Corona, G., Mascarin, M., Belluco, C., De Paoli, A., Fasola, G., Puglisi, F., & Miolo, G.
(2023). Prospective, Multicenter Phase II Trial of Non-Pegylated Liposomal Doxorubicin Combined with Ifosfamide in First-Line Treatment of Advanced/Metastatic Soft Tissue Sarcomas. Cancers, 15(20), 5036.
https://doi.org/10.3390/cancers15205036
